Patients with the greatest reduction in bone mineral density (BMD) appear to have the greatest benefit from treatment with aromatase inhibitors (AI) for hormone receptor-positive breast cancer, West Australian research shows.
The study, published in Cancer Medicine [link here], comprised 353 patients treated at the Royal Perth Hospital between January 1994 and December 2011.
Paired sequential BMD data was available from a baseline DEXA scan performed up to three months prior to, or within three months of commencement of an AI, and a follow-up DEXA scan at least six months after the initial scan undertaken while still on AI treatment.
The study found some evidence that the annual percent change in BMD at the lumbar spine was associated with breast cancer recurrence.
“In multivariate analysis, the difference between quartile 1, which showed the greatest reduction in BMD, and quartile 3, with substantially less reduction, was significant (HR = 3.02, 95% CI 1.15–7.90 p = 0.025).
“This fits with the hypothesis that change in LS BMD associates with AI efficacy, with those with the greatest reduction in BMD, quartile 1, having the greatest benefit from treatment.”
However, overall there was no significant association between recurrence and quartile of change of lumbar spine BMD (p = 0.15).
“The association between bone metastases and LS was similar to the association seen for overall recurrence with a non-significant reduction in bone metastases associated with greater BMD fall,” the study authors said.
As well, hip BMD reduction was not significantly associated with breast cancer recurrence.